J A Tami - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

J A Tami

Showing results (11-20 of 14) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 14 results.

Clinical and Experimental Immunology|June 17, 2005

Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1B R Yacyshyn, A Schievella, K L Sewell, et al.

Therapeutic Drug Monitoring|July 1, 1990

Procainamide-induced myasthenic crisisP J Godley, T A Morton, J A Karboski, et al.

American Journal of Hospital Pharmacy|November 1, 1986

Monoclonal antibody technologyJ A Tami, M D Parr, S A Brown, et al.

Gastroenterology|June 3, 1998

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's diseaseB R Yacyshyn, M B Bowen-Yacyshyn, L Jewell, et al.

Pageof 2

Search research articles

Showing results (11-20 of 14) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 14 results.

Clinical and Experimental Immunology|June 17, 2005

Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1B R Yacyshyn, A Schievella, K L Sewell, et al.

Therapeutic Drug Monitoring|July 1, 1990

Procainamide-induced myasthenic crisisP J Godley, T A Morton, J A Karboski, et al.

American Journal of Hospital Pharmacy|November 1, 1986

Monoclonal antibody technologyJ A Tami, M D Parr, S A Brown, et al.

Gastroenterology|June 3, 1998

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's diseaseB R Yacyshyn, M B Bowen-Yacyshyn, L Jewell, et al.

Pageof 2